Who are Celecoxib, COX-2 inhibitor; oral's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Celebrex, Cytotec, ropivacaine and ketorolac, aspirin (ASA), INF1.0 + IBU, ABS.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/celecoxib-cox-2-inhibitor-oral.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Celecoxib, COX-2 inhibitor; oral — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Celecoxib, COX-2 inhibitor; oral (Celecoxib, COX-2 inhibitor; oral) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: COX-2 inhibitor. Area: Osteoarthritis, Rheumatoid Arthritis, Pain.

phase 2 COX-2 inhibitor COX-2 Osteoarthritis, Rheumatoid Arthritis, Pain Small molecule Live · refreshed every 30 min

Target snapshot

Celecoxib, COX-2 inhibitor; oral (Celecoxib, COX-2 inhibitor; oral) — Pfizer. Celecoxib selectively inhibits COX-2, an enzyme involved in inflammation and pain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Celecoxib, COX-2 inhibitor; oral TARGET	Celecoxib, COX-2 inhibitor; oral	Pfizer	phase 2	COX-2 inhibitor	COX-2
Celebrex	celecoxib	Pfizer Inc. (originally Searle/Pharmacia)	marketed	Nonsteroidal Anti-inflammatory Drug [EPC]	COX-2	1998-12-31
Cytotec	Misoprostol	Pfizer	marketed	NSAID combined with prostaglandin analog	Cyclooxygenase (COX-1 and COX-2); Prostaglandin receptors	1988-01-01
ropivacaine and ketorolac	ropivacaine and ketorolac	University of Aarhus	marketed	Local anesthetic + NSAID combination	Voltage-gated sodium channels (ropivacaine); COX-1 and COX-2 (ketorolac)
aspirin (ASA)	aspirin (ASA)	Janssen Scientific Affairs, LLC	marketed	Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent	Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)
INF1.0 + IBU	INF1.0 + IBU	St. Justine's Hospital	marketed	Interferon alfa + NSAID combination	Interferon alfa receptor (IFNAR); COX-1 and COX-2
ABS	ABS	Teva Branded Pharmaceutical Products R&D, Inc.	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2036-05-27 — Celebrex · 10722456 · Formulation · US
2036-05-27 — Celebrex · 10799517 · Formulation · US
2036-05-27 — Celebrex · 9949990 · Formulation · US
2036-05-27 — Celebrex · 9795620 · Formulation · US
2036-05-27 — Celebrex · 9572819 · Formulation · US
2036-05-27 — Celebrex · 10376527 · Formulation · US

Sponsor landscape (COX-2 inhibitor class)

Organon and Co · 1 drug in this class
Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Celecoxib, COX-2 inhibitor; oral — Competitive Intelligence Brief. https://druglandscape.com/ci/celecoxib-cox-2-inhibitor-oral. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab